Sarcopenia in cirrhosis: from pathogenesis to interventions

Area of Science:

• Hepatology
• Muscle Physiology
• Metabolic Disorders

Background:

• Sarcopenia, severe muscle depletion, is a common complication in cirrhosis patients.
• It negatively impacts prognosis both before and after liver transplantation.
• The development of sarcopenia is multifactorial, stemming from an imbalance in protein synthesis and breakdown.

Purpose of the Study:

• To explore the multifactorial pathogenesis of sarcopenia in cirrhosis.
• To identify key molecular and physiological mechanisms driving muscle depletion.
• To inform the development of clinical trials for sarcopenia reversal in cirrhosis patients.

Main Methods:

• Review of existing literature on sarcopenia in cirrhosis.
• Analysis of metabolic, endocrine, and cellular factors influencing muscle mass.
• Examination of protein homeostasis and energy metabolism in chronic liver disease.

Main Results:

• Cirrhosis-associated sarcopenia involves hyperammonemia, increased autophagy, proteasomal activity, and impaired mitochondrial function.
• Endocrine factors like insulin resistance, IGF-1, corticosteroids, and testosterone play a role.
• Type II fast-twitch muscle fibers are preferentially affected in sarcopenic cirrhosis patients.

Conclusions:

• Reversing sarcopenia in cirrhosis may necessitate a multimodal approach combining nutritional, physical, and pharmacological interventions.
• Moderate exercise, adequate energy and protein intake are foundational.
• Individualized therapies targeting branched-chain amino acids, testosterone, carnitine, or ammonia levels warrant consideration.